Covid-19 roundup: J&J offers new data to support boosters — but some experts are not impressed; Thailand university's robotic arm maximizes vaccine vials
Amidst all the booster shot talk with Pfizer and Moderna, J&J on Wednesday offered new data that may lead to its own single-shot booster.
New interim data from Phase I/IIa trials showed that J&J’s booster generated a level of spike-binding antibodies that was 9-fold higher than 28 days after the first single-dose shot.
“We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” global head of R&D Mathai Mammen said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.